Endurant Capital Management LP Krystal Biotech, Inc. Transaction History

Endurant Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$39.81 - $88.24 $913,161 - $2.02 Million	-22,938 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$52.01 - $71.77 $1.19 Million - $1.65 Million	22,938 New	22,938 $1.2 Million
Q2 2019 Aug 14, 2019	SELL	$27.2 - $41.2 $1.66 Million - $2.52 Million	-61,155 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$19.86 - $32.9 $966,288 - $1.6 Million	48,655 Added 389.24%	61,155 $2.01 Million
Q4 2018 Feb 14, 2019	BUY	$15.03 - $25.38 $187,875 - $317,250	12,500 New	12,500 $260,000

310

24.4M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.89B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Endurant Capital Management LP with notifications on news.